161 related articles for article (PubMed ID: 11223553)
1. Pharmacodynamic modeling of the entire time course of leukopenia after a 3-hour infusion of paclitaxel.
Minami H; Sasaki Y; Watanabe T; Ogawa M
Jpn J Cancer Res; 2001 Feb; 92(2):231-8. PubMed ID: 11223553
[TBL] [Abstract][Full Text] [Related]
2. Indirect-response model for the time course of leukopenia with anticancer drugs.
Minami H; Sasaki Y; Saijo N; Ohtsu T; Fujii H; Igarashi T; Itoh K
Clin Pharmacol Ther; 1998 Nov; 64(5):511-21. PubMed ID: 9834043
[TBL] [Abstract][Full Text] [Related]
3. [Effect of G-CSF (nartograstim) on neutropenia (leukopenia) induced by taxane in metastatic breast cancer--time-course changes in neutrophil and leukocyte counts].
Kinoshita J; Haga S; Shimizu T; Imamura H; Watanabe O; Nagumo H; Utada Y; Okabe T; Kimura K; Hirano A; Kajiwara T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):815-9. PubMed ID: 11432350
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.
Ohtsu T; Sasaki Y; Tamura T; Miyata Y; Nakanomyo H; Nishiwaki Y; Saijo N
Clin Cancer Res; 1995 Jun; 1(6):599-606. PubMed ID: 9816021
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results from a randomized trial.
Mross K; Häring B; Holländer N; Mielke S; Behringer D; Massing U; Unger C
Onkologie; 2002 Dec; 25(6):503-8. PubMed ID: 12566894
[TBL] [Abstract][Full Text] [Related]
6. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
[TBL] [Abstract][Full Text] [Related]
7. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression.
Karlsson MO; Molnar V; Bergh J; Freijs A; Larsson R
Clin Pharmacol Ther; 1998 Jan; 63(1):11-25. PubMed ID: 9465838
[TBL] [Abstract][Full Text] [Related]
8. Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
Cancer Chemother Pharmacol; 2009 May; 63(6):1035-48. PubMed ID: 18791717
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer.
Tsushima T; Kasai H; Tanigawara Y
Cancer Chemother Pharmacol; 2020 Oct; 86(4):487-495. PubMed ID: 32930844
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic modeling of prolonged administration of etoposide.
Minami H; Ratain MJ; Ando Y; Shimokata K
Cancer Chemother Pharmacol; 1996; 39(1-2):61-6. PubMed ID: 8995500
[TBL] [Abstract][Full Text] [Related]
11. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Hudis CA; Seidman AD; Crown JP; Balmaceda C; Freilich R; Gilewski TA; Hakes TB; Currie V; Lebwohl DE; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
J Clin Oncol; 1996 Jan; 14(1):58-65. PubMed ID: 8558221
[TBL] [Abstract][Full Text] [Related]
12. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics of a 1-h paclitaxel infusion.
Mross K; Holländer N; Hauns B; Schumacher M; Maier-Lenz H
Cancer Chemother Pharmacol; 2000; 45(6):463-70. PubMed ID: 10854133
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel.
Fetterly GJ; Grasela TH; Sherman JW; Dul JL; Grahn A; Lecomte D; Fiedler-Kelly J; Damjanov N; Fishman M; Kane MP; Rubin EH; Tan AR
Clin Cancer Res; 2008 Sep; 14(18):5856-63. PubMed ID: 18794097
[TBL] [Abstract][Full Text] [Related]
15. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity.
Venturini M; Lunardi G; Del Mastro L; Vannozzi MO; Tolino G; Numico G; Viale M; Pastrone I; Angiolini C; Bertelli G; Straneo M; Rosso R; Esposito M
J Clin Oncol; 2000 May; 18(10):2116-25. PubMed ID: 10811677
[TBL] [Abstract][Full Text] [Related]
16. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
Seidman AD; Hochhauser D; Gollub M; Edelman B; Yao TJ; Hudis CA; Francis P; Fennelly D; Gilewski TA; Moynahan ME; Currie V; Baselga J; Tong W; O'Donaghue M; Salvaggio R; Auguste L; Spriggs D; Norton L
J Clin Oncol; 1996 Jun; 14(6):1877-84. PubMed ID: 8656256
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.
Panday VR; ten Bokkel Huinink WW; Vermorken JB; Rosing H; Koopman FJ; Swart M; Schellens JH; Beijnen JH
Pharmacol Res; 1999 Jul; 40(1):67-74. PubMed ID: 10378993
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.
Gelderblom H; Mross K; ten Tije AJ; Behringer D; Mielke S; van Zomeren DM; Verweij J; Sparreboom A
J Clin Oncol; 2002 Jan; 20(2):574-81. PubMed ID: 11786588
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic drug monitoring of paclitaxel (Zisu) in cancer patients.
Wu D; Liang Y; Liu Q
J Environ Pathol Toxicol Oncol; 2000; 19(1-2):77-80. PubMed ID: 10905511
[TBL] [Abstract][Full Text] [Related]
20. [Weekly paclitaxel therapy for metastatic breast cancer].
Kokufu I; Taniguchi H; Kimura F; Fukuda K; Yamamoto M; Yano T; Yamada K
Gan To Kagaku Ryoho; 2002 Feb; 29(2):221-6. PubMed ID: 11865627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]